Johnson & Johnson vs. Danaher: Which Healthcare Stock Looks Better Positioned Following Earnings?
Johnson & Johnson (NYSE: JNJ ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 billion, above analysts' average estimate of about $25.05 billion. Adjus
Yahoo Finance — 31 July 2026
Text:
15
0
0
Johnson & Johnson (NYSE: JNJ ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 billion, above analyst
Read Full Story at Yahoo Finance → Sources
📈 Markets & Finance
Trump finalizes new tariffs on dozens of countries
📈 Markets & Finance
Little Movement Seen For Thai Stock Market
📈 Markets & Finance
Where Will Solana Be in 3 Years?
📈 Markets & Finance
Ethereum Foundation adds SEAL 911 co-founder to board as privacy focus grows
📈 Markets & Finance
Sophie Cunningham shares special moment with Brittney Griner before Fever-Sun game
📈 Markets & Finance
Analysts predict Chinese stock market rebound following U.S. election results
